Clinical Trials Logo

Chemotherapy clinical trials

View clinical trials related to Chemotherapy.

Filter by:

NCT ID: NCT01313559 Terminated - Prostate Cancer Clinical Trials

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Start date: June 2011
Phase: Phase 2
Study type: Interventional

This is an open label randomized phase II study for prostate cancer patients who have disease progression after hormonal therapy. SOM230 LAR (Pasireotide) binds to its receptor of prostate cancer cells and can prevent them from growing. Everolimus works by targeting a cell survival factor in prostate cancer. The combination of these drugs may work better for the treatment of prostate cancer without toxic chemotherapy. Patients will receive either SOM230 LAR (group A) or SOM230 LAR in combination with Everolimus (group B).

NCT ID: NCT01249001 Terminated - Nausea Clinical Trials

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents

Start date: October 2010
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to compare the absorption of a prepared aprepitant oral suspension with that of the aprepitant capsule in children being treated with chemotherapy agents that are likely to cause vomiting.

NCT ID: NCT01067989 Terminated - Chemotherapy Clinical Trials

Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer

Start date: March 2010
Phase: Phase 2
Study type: Interventional

Low-dose metronomic(LDM)chemotherapy as well as anti-inflammatory agents and bisphosphonates have shown anti-angiogenic properties on tumor vasculature. This study is meant to test the therapeutic potential of an anti-angiogenic treatment strategy by combining all these agents for metastatic breast cancer patients.

NCT ID: NCT00926354 Terminated - Clinical trials for Chemotherapy Induced Thrombocytopenia

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

Start date: August 2009
Phase: Phase 2
Study type: Interventional

Chemotherapy Induced Thrombocytopenia is a common side-effect of bone marrow suppression as a result of a chemotherapy treatment. AS101 is a tellurium based small compound with immunomodulating characteristics which attributed to the direct inhibition of the anti-inflammatory cytokine IL-10. AS101 was previously shown to induce a significant reduction in thrombocytopenia that accompany cancer therapy with no major toxicity . This phase II randomized open study will evaluate the efficacy of AS101 for the treatment of chemotherapy induced thrombocytopenia in patients with various solid tumors.

NCT ID: NCT00888810 Terminated - Cancer Clinical Trials

Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer

TOPO-LAPA
Start date: March 2008
Phase: Phase 2
Study type: Interventional

The objective of the trial was to evaluate the efficacy of the association of topotecan and lapatinib in patients who failed first line platinum-based chemotherapy within 12 months.

NCT ID: NCT00869804 Terminated - Breast Neoplasms Clinical Trials

Heading Off Peripheral Neuropathy With Exercise

HOPE
Start date: March 25, 2009
Phase: N/A
Study type: Interventional

Chemotherapy for the treatment of breast cancer can affect nerves and muscles leading to loss of sensation in the hands and feet for feeling hot and cold, difficulty walking, and muscle weakness. This study will explore if exercises such as walking and strength training may prove helpful in preventing or lessening chemotherapy-induced peripheral neuropathy from chemotherapy, making the therapy easier to tolerate and increasing overall quality of life.

NCT ID: NCT00818259 Terminated - Clinical trials for Chemotherapy-Induced Nausea and Vomiting

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)

Start date: February 5, 2009
Phase: Phase 1
Study type: Interventional

This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.

NCT ID: NCT00495378 Terminated - Cancer Clinical Trials

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

Start date: November 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study was to determine if alternate dosing of Epoetin alfa was effective in maintaining hemoglobin levels in patients with chemotherapy related anemia.

NCT ID: NCT00380874 Terminated - Clinical trials for Chemotherapy-Induced Peripheral Neuropathy

Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer

Start date: January 2007
Phase: Phase 4
Study type: Interventional

Prevention and treatment of the severity of symptoms of chemotherapy-induced peripheral neuropathy.